Featured
-
-
News |
Vaccine innovation and COVID’s collateral damage — the week in infographics
Nature highlights three key infographics from the week in science and research.
-
News Explainer |
COVID vaccine immunity is waning — how much does that matter?
As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving.
- Elie Dolgin
-
News |
COVID-vaccine booster shot shows promise in Israeli study
Risk of severe disease drops by factor of almost 20 in people over 60 — but some dispute the benefits of offering a third dose.
- Max Kozlov
-
News |
Did the coronavirus jump from animals to people twice?
A preliminary analysis of viral genomes suggests the COVID-19 pandemic might have multiple animal origins — but the findings still have to be peer reviewed.
- Smriti Mallapaty
-
News & Views |
Ebola virus can lie low and reactivate after years in human survivors
A genomic comparison of Ebola virus from the 2021 outbreak in Guinea with sequences from the West African outbreak that ended in 2016 suggests that the virus can remain latent in human survivors for an extended period of time.
- Robert F. Garry
-
News Round-Up |
COVID research prizes, CRISPR-like enzymes and a face-mask trial
The latest science news, in brief.
-
News |
The fight to manufacture COVID vaccines in lower-income countries
Drug companies and wealthy countries are facing increased pressure to partner with firms in the global south but are reluctant to relinquish control.
- Amy Maxmen
-
Article |
Structural insights into hepatitis C virus receptor binding and entry
Crystal structures of the hepatitis C virus (HCV) glycoprotein E2 in complex with CD81 reveal the conformational changes that occur in E2 after binding of CD81 and the effects of pH on binding affinity.
- Ashish Kumar
- , Reafa A. Hossain
- & Joseph Marcotrigiano
-
Article |
Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks
The viral lineage responsible for the February 2021 outbreak of Ebola virus disease in Guinea is nested within a clade that predominantly consists of genomes sampled during the 2013–2016 epidemic, suggesting that the virus might have re-emerged after a long period of latency within a previously infected individual.
- Alpha Kabinet Keita
- , Fara R. Koundouno
- & N’. Faly Magassouba
-
Correspondence |
Africa: invest in local manufacturing of COVID-19 vaccines
- James Ayodele
- & Sylvain Boko
-
News Feature |
The tangled history of mRNA vaccines
Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough.
- Elie Dolgin
-
Article |
Virus-induced senescence is a driver and therapeutic target in COVID-19
Virus-induced senescence is a central pathogenic feature in COVID-19, and senolytics, which promote apoptosis of senescent cells, can reduce disease severity in hamsters,mice, as well as humans infected with SARS-CoV-2.
- Soyoung Lee
- , Yong Yu
- & Clemens A. Schmitt
-
News |
COVID in kids and fossil-fuel limits — the week in infographics
Nature highlights three key infographics from the week in science and research.
-
News |
Pivotal climate summit dogged by COVID and equity concerns
Environmental network calls for delay to the November meeting, but many developing countries and the host nation vow to press on in face of climate threats.
- Jeff Tollefson
-
News |
Trove of CRISPR-like gene-cutting enzymes found in microbes
The search for a CRISPR enzyme’s ancestors has revealed more than one million potential genome-editing tools.
- Heidi Ledford
-
News |
How COVID is derailing the fight against HIV, TB and malaria
The pandemic’s effects on efforts to thwart other infectious diseases could exceed the direct impact of COVID-19.
- Leslie Roberts
-
News |
Face masks for COVID pass their largest test yet
A rigorous study finds that surgical masks are highly protective, but cloth masks fall short.
- Lynne Peeples
-
Article |
Bioaccumulation of therapeutic drugs by human gut bacteria
An analysis of the interactions between 15 drugs and 25 gut bacterial strains shows that bioaccumulation of drugs within bacterial cells is another mechanism through which gut microorganisms can alter drug availability and efficacy.
- Martina Klünemann
- , Sergej Andrejev
- & Kiran R. Patil
-
-
News Feature |
Kids and COVID: why young immune systems are still on top
Innate immunity might be the key to why children have fared better with the virus. But the Delta variant poses fresh unknowns.
- Smriti Mallapaty
-
Article
| Open AccessSARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
A study of SARS-CoV-2 variants examining their transmission, infectivity, and potential resistance to therapies provides insights into the biology of the Delta variant and its role in the global pandemic.
- Petra Mlcochova
- , Steven A. Kemp
- & Ravindra K. Gupta
-
Article |
Programmable RNA targeting with the single-protein CRISPR effector Cas7-11
Cas7-11—the fusion of a putative Cas11 domain and four Cas7 subunits—cleaves RNA without detectable non-specific activity and, when optimized for RNA knockdown and editing in mammalian cells, has no effects on cell viability.
- Ahsen Özcan
- , Rohan Krajeski
- & Jonathan S. Gootenberg
-
Article |
Structure of Geobacter pili reveals secretory rather than nanowire behaviour
Structural, functional and localization studies reveal that Geobacter sulfurreducens pili cannot behave as microbial nanowires, instead functioning in a similar way to secretion pseudopili to export cytochrome nanowires that are essential for extracellular electron transfer.
- Yangqi Gu
- , Vishok Srikanth
- & Nikhil S. Malvankar
-
News |
Rogue antibodies involved in almost one-fifth of COVID deaths
The self-targeting antibodies attack type 1 interferons that play a key role in fighting infection.
- Diana Kwon
-
Article |
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
C-type lectins and SIGLEC1 function as attachment receptors for SARS-CoV-2 and enhance ACE2-mediated infection.
- Florian A. Lempp
- , Leah B. Soriaga
- & Davide Corti
-
News |
COVID in Venezuela, health trials suppressed — the week in infographics
Nature highlights three key infographics from the week in science and research.
-
News |
US COVID origins report: researchers pleased with scientific approach
Intelligence investigation is inconclusive on virus’s origins, but finds SARS-CoV-2 wasn’t weaponized and is unlikely to have been engineered.
- Amy Maxmen
-
Career Column |
Five hundred days between pay cheques: the road I took to revive my career
A global career move left one member of a scientist couple unemployed during the pandemic. Here’s what he learnt.
- Nuwan Bandara
-
Article |
Burden and characteristics of COVID-19 in the United States during 2020
Data-driven modelling including numbers of cases and population movements is used to simulate the COVID-19 pandemic in the United States in 2020, providing insights into the transmission of the disease.
- Sen Pei
- , Teresa K. Yamana
- & Jeffrey Shaman
-
Comment |
Origins of SARS-CoV-2: window is closing for key scientific studies
Authors of the March WHO report into how COVID-19 emerged warn that further delay makes crucial inquiry biologically difficult.
- Marion Koopmans
- , Peter Daszak
- & John Watson
-
Career Column |
How Zoom helped the neurotypical world hear my autistic voice
Anya Lawrence says pandemic videoconferencing has brought her closer to her colleagues and others in the world of science.
- Anya Lawrence
-
News Round-Up |
Babbling bats, autocorrected genes and COVID antibodies
The latest science news, in brief.
-
News |
The Venezuelan health-care workers secretly collecting COVID stats
Faced with government suppression and limited resources, doctors and nurses are quietly working with research networks to report reliable data.
- Luke Taylor
-
Correspondence |
Home laboratory: interactive science from the kitchen
- Poorti Kathpalia
- , Arpita Konar
- & Beena Pillai
-
Article
| Open AccessEmergence and expansion of SARS-CoV-2 B.1.526 after identification in New York
The dynamics of the spread of the SARS-CoV-2 variant B.1.526 suggest that resistance to neutralization by antibodies may evolve in other variants and contribute to the spread of COVID-19.
- Medini K. Annavajhala
- , Hiroshi Mohri
- & Anne-Catrin Uhlemann
-
News |
How Nature’s COVID coverage has made a difference
We analysed the impact of Nature’s coronavirus journalism and opinion. Here’s what we found.
- Julian Nowogrodzki
-
News Feature |
COVID vaccines and blood clots: what researchers know so far
Scientists are trying to understand why a small number of people develop a mysterious clotting disorder after receiving a COVID jab.
- Heidi Ledford
-
Technology Feature |
Innovative tools take aim at antibiotic-resistant microbes
Diagnostics that rely on bacterial movements, genomics and machine learning could help to address a global crisis.
- Jyoti Madhusoodanan
-
Nature Podcast |
Coronapod: How Delta is changing the game
New studies are starting to shed light on how and why the Delta COVID variant has become so dominant
- Noah Baker
- & Emma Stoye
-
News |
The mutation that helps Delta spread like wildfire
A key amino-acid change might underlie the coronavirus variant’s ferocious infectivity.
- Ewen Callaway
-
News |
Delta’s rise is fuelled by rampant spread from people who feel fine
People infected with the Delta variant generally do not have COVID-19 symptoms until two days after they start shedding the coronavirus.
- Smriti Mallapaty
-
News |
COVID vaccines protect against Delta, but their effectiveness wanes
Massive UK study of COVID-19 cases shows that people who are jabbed have good immunity at first, but quickly become more vulnerable to the fast-spreading Delta variant.
- Katharine Sanderson
-
News |
Antibodies reveal who’s protected by Moderna’s COVID vaccine
Trial results add to growing evidence that low levels of ‘neutralizing’ antibodies are a marker of vulnerability to COVID-19.
- Ewen Callaway
-
News |
Decades-old SARS virus infection triggers potent response to COVID vaccines
Dramatic antibody production in people infected during the 2002–04 outbreak furthers hopes of a vaccine against many coronaviruses.
- Smriti Mallapaty
-
News Round-Up |
Mars rover mishap, Beta variant’s toll and UK open access
The latest science news, in brief.
-
Article |
Molecular basis for DarT ADP-ribosylation of a DNA base
Structural and mechanistic data of the ADP-ribosyltransferase DarT demonstrate the role of ADP-ribosylation of DNA by this enzyme in generating toxicity and regulating cellular signalling processes in bacteria.
- Marion Schuller
- , Rachel E. Butler
- & Ivan Ahel
-
Article |
Cotranslational prolyl hydroxylation is essential for flavivirus biogenesis
A proteomics-based strategy is used to examine how three different RNA viruses (polio, Zika and dengue) remodel translation in the host to recruit host machineries necessary for the production of viral proteins.
- Ranen Aviner
- , Kathy H. Li
- & Raul Andino
-
-
News Q&A |
Iran hopes to defeat COVID with home-grown crop of vaccines
Nature talks to vaccine developer Kayhan Azadmanesh about efforts in Iran to develop ten or more COVID jabs, two of which have been approved for use.
- Smriti Mallapaty
Browse broader subjects
Browse narrower subjects
- Antimicrobials
- Applied microbiology
- Archaea
- Bacteria
- Bacteriology
- Bacteriophages
- Biofilms
- Biogeochemistry
- Cellular microbiology
- Clinical microbiology
- Microbial communities
- CRISPR-Cas systems
- Environmental microbiology
- Fungi
- Industrial microbiology
- Infectious-disease diagnostics
- Microbial genetics
- Parasitology
- Pathogens
- Phage biology
- Policy and public health in microbiology
- Vaccines
- Virology